United States Drug Patent 9,944,651: Avapritinib Claims, Scope, Expiration, and Patent Landscape
US Patent No. 9,944,651 protects avapritinib, marketed by Blueprint Medicines as AYVAKIT. Its claims cover the avapritinib compound, pharmaceutically acceptable salts, pharmaceutical compositions, and treatment of GIST, mastocytosis, and AML, including genetically defined KIT and PDGFRA populations. The patent issued April 17, 2018, and has an estimated patent-term expiration in February 2034, subject to any applicable patent-term adjustment or extension recorded by the USPTO and FDA.
The patent is commercially important because its method claims reach the principal biomarker-defined populations for which avapritinib was developed, including PDGFRA D842V GIST and KIT D816V mastocytosis. It is one element of a broader AYVAKIT patent estate that includes compound, formulation, dosing, and method-of-use protection.
What drug does US Patent 9,944,651 protect?
US 9,944,651 protects avapritinib, a selective inhibitor of KIT and PDGFRA tyrosine kinases. Avapritinib is an orally administered small molecule, not a biologic. It is sold in the United States under the AYVAKIT brand.
The patent’s chemical claims correspond to avapritinib and its pharmaceutically acceptable salts. The compound claims are the strongest claims in the patent because they are not limited to a specific disease, mutation, dose, or patient population.
| Item |
Information |
| Patent |
US 9,944,651 B2 |
| Active ingredient |
Avapritinib |
| Brand |
AYVAKIT |
| Developer and marketer |
Blueprint Medicines Corporation |
| Therapeutic class |
KIT and PDGFRA tyrosine kinase inhibitor |
| Patent issue date |
April 17, 2018 |
| Principal protected uses |
GIST, mastocytosis, AML |
| Key biomarkers |
PDGFRA D842V; KIT exon 17, including D816V |
| Estimated expiration |
February 2034, before any applicable term adjustment or extension |
| FDA product type |
Small-molecule prescription drug |
The claim set is directed to the molecule represented in the patent drawings. The compound claims should therefore be read together with the structural definitions and chemical nomenclature in the issued patent, rather than from the abbreviated text-only claim transcription.
What are the independent claims in US 9,944,651?
The patent has four practical claim categories.
Claims 1 and 2: Avapritinib and salts
Claims 1 and 2 cover the claimed chemical entity and a pharmaceutically acceptable salt of that entity. These claims are composition-of-matter claims.
Their scope is not restricted to:
- GIST;
- mastocytosis;
- AML;
- a particular mutation;
- a particular dosage;
- a particular formulation; or
- a particular line of therapy.
A valid composition-of-matter claim generally creates the primary barrier to a competing generic product containing the same active ingredient. A generic applicant could challenge the claims through an Abbreviated New Drug Application paragraph IV certification, but commercial entry would normally remain exposed to an infringement action and a potential 30-month stay under the Hatch-Waxman Act.
Claim 3: Pharmaceutical composition
Claim 3 covers a pharmaceutical composition containing avapritinib or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.
This claim reaches conventional oral dosage forms, including tablets or capsules, if they contain the claimed active ingredient and an acceptable pharmaceutical carrier. It is broader than a claim limited to a specific excipient, release profile, strength, or manufacturing process.
The claim does not, on its face, establish protection for every possible formulation improvement. A later formulation patent would need separate limitations, such as a particular solid form, particle-size distribution, excipient system, dissolution profile, or manufacturing method.
Claim 4: Disease-treatment method
Claim 4 covers administering a therapeutically effective amount of avapritinib to treat:
- GIST;
- mastocytosis; or
- AML.
The disease claim is a method-of-treatment claim. It is narrower than the compound claims because infringement requires the claimed therapeutic use. It can still be important against a generic applicant where the FDA-approved labeling directs use in a patented indication.
How do the dependent claims expand protection?
Claims 5 through 24 define biomarker, disease-subtype, treatment-history, and disease-severity populations.
| Claims |
Protected population or limitation |
| 5-11 |
GIST and specified molecular or treatment-resistant populations |
| 6 |
GIST with PDGFRA D842V in exon 18 |
| 7, 9, 10 |
GIST with KIT exon 17 mutations, including D816V |
| 8 |
GIST refractory to imatinib, sunitinib, and/or regorafenib |
| 11 |
Unresectable GIST |
| 12-20 |
Mastocytosis and defined systemic mastocytosis subtypes |
| 18-20 |
Mastocytosis with KIT exon 17 mutations, including D816V |
| 21-24 |
AML with KIT exon 17 mutations, including D816V |
PDGFRA D842V GIST
Claim 6 specifically covers GIST patients with a PDGFRA D842V mutation in exon 18. This is a commercially significant claim because PDGFRA D842V is a well-recognized driver mutation associated with resistance to several earlier GIST therapies.
The claim is narrower than the compound claim but closely aligned with avapritinib’s clinical differentiation. A product containing avapritinib could infringe the compound claims regardless of whether it is prescribed for PDGFRA-mutated GIST. The method claim creates a separate layer of protection for the biomarker-defined use.
KIT exon 17 and D816V disease
Claims 7, 9, 10, 18, 19, 20, and 22 through 24 address KIT exon 17 mutations, particularly D816 and D816V.
These claims cover:
- GIST with KIT exon 17 mutations;
- mastocytosis with KIT exon 17 mutations;
- AML with KIT exon 17 mutations; and
- the D816V mutation as a specific subset.
The D816V limitation is especially relevant to systemic mastocytosis. The mutation is a central molecular feature of many systemic mastocytosis cases and is a key reason avapritinib has clinical and regulatory value in that disease.
Refractory GIST
Claim 8 covers patients refractory to imatinib, sunitinib, and/or regorafenib. This claim tracks the treatment sequence used in advanced GIST and targets patients who have exhausted or failed earlier approved tyrosine kinase inhibitors.
The use of “and/or” gives the claim practical breadth across patients refractory to one or more of the listed agents. It does not require failure of all three drugs.
Mastocytosis subtypes
Claims 12 through 17 cover mastocytosis generally and defined systemic mastocytosis subtypes:
- indolent systemic mastocytosis;
- smoldering systemic mastocytosis;
- aggressive systemic mastocytosis;
- systemic mastocytosis with associated hematologic non-mast-cell disease; and
- mast-cell leukemia.
The claims also identify cutaneous mastocytosis. The patent therefore extends beyond the narrow advanced systemic mastocytosis population that formed the basis of the initial mastocytosis approval.
What FDA approvals and exclusivity periods affect US 9,944,651?
AYVAKIT received FDA approval in several stages.
| FDA milestone |
Date |
Commercial significance |
| Initial approval for unresectable or metastatic GIST with PDGFRA exon 18 mutations, including D842V |
January 9, 2020 |
Established the first commercial indication |
| Approval for advanced systemic mastocytosis |
May 22, 2021 |
Added aggressive systemic mastocytosis and SM-AHN |
| Approval for indolent systemic mastocytosis |
May 22, 2023 |
Expanded treatment into a larger systemic mastocytosis population |
The FDA approved AYVAKIT as an orphan drug for certain rare diseases. Orphan-drug exclusivity is indication-specific and operates separately from patent rights. The advanced systemic mastocytosis approval received seven years of orphan exclusivity, generally extending to May 2028. The indolent systemic mastocytosis approval received a separate orphan-exclusivity period, generally extending to May 2030, subject to the FDA’s official regulatory records.
Orphan exclusivity does not prevent all generic activity involving the same active ingredient. It principally restricts FDA approval of the same drug for the same orphan indication during the applicable period, subject to statutory exceptions. Patent expiration remains the more important long-term issue because the composition-of-matter patent is expected to extend into 2034.
When does avapritinib lose patent exclusivity?
The base 20-year term for US 9,944,651 is tied to the relevant nonprovisional filing and priority history. Public patent records identify an estimated expiration in February 2034. The effective date may differ if the patent has recorded patent-term adjustment or qualifies for patent-term extension.
A practical exclusivity timeline is:
| Protection |
Approximate endpoint |
| Initial GIST orphan exclusivity |
January 2027 |
| Advanced systemic mastocytosis orphan exclusivity |
May 2028 |
| Indolent systemic mastocytosis orphan exclusivity |
Approximately May 2030 |
| US 9,944,651 patent term |
Approximately February 2034 |
| Earliest ordinary small-molecule generic opportunity |
Potentially after applicable patent and regulatory barriers expire |
A generic applicant could seek earlier entry through a paragraph IV challenge. The existence of a later patent challenge would depend on the patents listed in the FDA Orange Book at the time of filing and the scope of the applicant’s proposed label.
What is the Orange Book status of avapritinib?
AYVAKIT is an FDA-approved small-molecule drug subject to Orange Book listing. US 9,944,651 is part of the patent protection associated with avapritinib. The listed protection should be evaluated alongside later AYVAKIT patents covering additional methods, formulations, dosing regimens, and patient populations.
The Orange Book analysis must distinguish:
- patents listed against the reference drug;
- patents that cover the active ingredient;
- patents that cover a particular FDA-approved use; and
- patents that may be relevant to a generic’s proposed label.
An ANDA applicant can file a paragraph IV certification against a listed patent. Blueprint could then bring an infringement action within 45 days, triggering the statutory 30-month stay of approval unless the litigation is resolved earlier or the stay is otherwise terminated.
No widely reported US paragraph IV launch challenge or final generic approval for avapritinib has established market entry before the principal patent term. The absence of a public challenge at a particular time does not eliminate the possibility of a later filing.
Which companies are challenging the avapritinib patent estate?
Publicly available information does not show a major commercial generic launch against AYVAKIT. The principal competitive risk is therefore prospective rather than an established generic market event.
Potential challengers would likely include:
- large generic manufacturers with oncology portfolios;
- specialty-generic companies focused on kinase inhibitors; and
- contract manufacturers or licensees seeking an ANDA partner.
Biosimilar competition is not relevant. Avapritinib is a chemically synthesized small molecule, so the applicable FDA pathway is an ANDA or, in some circumstances, a 505(b)(2) application. The biosimilar pathway under the Public Health Service Act does not apply.
How strong is the patent estate for avapritinib?
US 9,944,651 is strong at the active-ingredient level because claims 1 and 2 are composition-of-matter claims. Those claims do not depend on proving a particular clinical indication. A successful invalidity challenge could materially reduce protection because the compound claims are the central barrier to a generic containing avapritinib.
The method claims are narrower but commercially aligned with the approved uses. They are strongest where:
- the prescribed indication is expressly covered;
- the patient population has PDGFRA D842V or KIT D816V;
- the product label directs the patented use; and
- the generic applicant seeks a label that includes the protected indication.
The claim estate is weaker for unapproved AML use because FDA approval and commercial prescribing do not automatically establish infringement. AML claims may still have strategic value if clinical development produces an approved label or if prescribing evidence supports induced-infringement allegations.
What patent litigation and settlements affect AYVAKIT?
No prominent US patent settlement has publicly established an authorized generic or fixed generic-entry date for avapritinib under US 9,944,651. The key litigation risk remains a future ANDA paragraph IV case involving the composition-of-matter claims or later-listed AYVAKIT patents.
A future case would likely focus on:
- claim construction of the avapritinib structure;
- anticipation and obviousness;
- enablement and written description;
- salt and solid-form coverage;
- Orange Book listing eligibility;
- induced infringement based on the proposed generic label; and
- the scope of any carve-out for unpatented indications.
How does avapritinib compare with competing GIST and mastocytosis drugs?
| Drug |
Principal target or mechanism |
Main commercial role |
Relationship to avapritinib |
| Imatinib |
KIT, PDGFRA, BCR-ABL |
Earlier-line GIST |
Common prior therapy; resistance is addressed in patent claim 8 |
| Sunitinib |
KIT and other kinases |
Second-line GIST |
Prior therapy in refractory GIST |
| Regorafenib |
Multikinase inhibitor |
Later-line GIST |
Prior therapy in refractory GIST |
| Ripretinib |
Switch-control KIT inhibitor |
Later-line GIST |
Direct commercial competitor in advanced GIST |
| Midostaurin |
Multikinase inhibitor, including KIT |
Advanced systemic mastocytosis |
Competes in systemic mastocytosis |
| Avapritinib |
Selective KIT and PDGFRA inhibitor |
PDGFRA-mutated GIST and systemic mastocytosis |
Protected by US 9,944,651 and related patents |
Avapritinib’s patent value is concentrated in molecularly defined disease. The PDGFRA D842V and KIT D816V populations are narrower than the entire GIST or mastocytosis markets, but they are clinically differentiated and difficult to substitute with earlier kinase inhibitors.
What revenue exposure is tied to the patent estate?
AYVAKIT generated approximately $479 million in US product revenue in 2024, according to Blueprint Medicines’ public financial reporting. Revenue is exposed to three main patent risks:
- early generic entry through a successful paragraph IV challenge;
- invalidation or narrowing of compound claims; and
- erosion of pricing after patent expiry, even if orphan exclusivity delays some indication-specific approvals.
The commercial exposure is increasing as AYVAKIT expands from mutation-defined GIST into systemic mastocytosis. That expansion increases the importance of method-of-use patents and orphan exclusivity, while the composition-of-matter patent remains the principal long-term protection.
What manufacturing and geographic barriers remain?
US 9,944,651 primarily protects the compound, pharmaceutical composition, and therapeutic uses. It does not, based on the supplied claims, create a standalone claim to every manufacturing route, polymorph, crystal form, intermediate, or process parameter.
Manufacturing risk may instead arise from separate patents covering:
- synthetic intermediates;
- alternative routes of synthesis;
- crystalline forms;
- particle engineering;
- tablet manufacture;
- impurity controls; and
- formulation stability.
The patent is a US right. Equivalent foreign family members must be reviewed separately in Europe, Japan, Canada, China, and other markets. Foreign prosecution can produce narrower claims, different expiration dates, and different validity outcomes. A US freedom-to-operate conclusion cannot be extended automatically to other jurisdictions.
Key Takeaways
- US 9,944,651 is an avapritinib patent owned by Blueprint Medicines.
- Claims 1 and 2 are composition-of-matter claims covering avapritinib and pharmaceutically acceptable salts.
- Claim 3 covers pharmaceutical compositions containing avapritinib.
- Claims 4 through 24 cover GIST, mastocytosis, and AML treatment.
- The most commercially important method claims address PDGFRA D842V GIST and KIT D816V mastocytosis.
- The patent is expected to expire in approximately February 2034, subject to recorded term adjustment or extension.
- AYVAKIT has FDA approvals for PDGFRA-mutated GIST, advanced systemic mastocytosis, and indolent systemic mastocytosis.
- Biosimilar competition is not applicable because avapritinib is a small molecule.
- Generic entry would most likely occur through an ANDA, potentially involving a paragraph IV challenge.
- The patent estate is strongest at the active-ingredient level and is supplemented by later formulation, dosing, and method-of-use patents.
FAQs
Is US 9,944,651 a composition-of-matter patent?
Yes. Claims 1 and 2 cover avapritinib and its pharmaceutically acceptable salts. Those claims are broader than disease-specific treatment claims.
Does US 9,944,651 cover AYVAKIT for PDGFRA D842V GIST?
Yes. Claim 6 specifically covers treating GIST in a patient with a PDGFRA D842V mutation in exon 18.
Does the patent cover KIT D816V systemic mastocytosis?
Yes. Claims 18 through 20 cover mastocytosis with KIT exon 17 mutations, including KIT D816V.
Can a generic company launch avapritinib before 2034?
A launch before the estimated patent expiry would generally require a successful patent challenge, a noninfringing product and label, a license or settlement, or another legally permitted entry route.
Are avapritinib biosimilars expected?
No. Avapritinib is a chemically synthesized small molecule. Competitive products would generally proceed through the ANDA or 505(b)(2) pathways rather than the biosimilar pathway.
References
-
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,944,651, pyrrolopyrimidine compounds and methods of use thereof. https://patents.google.com/patent/US9944651B2/en
-
U.S. Food and Drug Administration. (2020). FDA approves avapritinib for unresectable or metastatic GIST with PDGFRA exon 18 mutations. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2021). FDA approves avapritinib for advanced systemic mastocytosis. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2023). FDA approves avapritinib for adults with indolent systemic mastocytosis. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
Blueprint Medicines Corporation. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024. https://ir.blueprintmedicines.com/financial-information/sec-filings